Grifols, a developer of therapies with plasma-derived proteins, will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.   The new drug would provide immediate post-exposure protection against the virus and would be useful as a complement to the vaccine in the early phase after vaccination. In addition,...